Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1b lemzoparlimab dose-escalation and expansion study in relapsed/refractory multiple myeloma
jRCT2071220010Phase 1Suspended
- Sponsor
- AbbVie Inc.
- Start
- Jun 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
01
Overview
Phase 1, open-label trial of lemzoparlimab in multiple myeloma (MM) (9 arms), sponsored by AbbVie Inc. Primary endpoint: Dose Limiting Toxicities. Started Jun 2022; status: suspended.
02
Drugs
lemzoparlimab
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on jRCT2071220010.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2071220010.